Becton Dickinson and Co (BDX) : Fukoku Mutual Life Insurance Co scooped up 200 additional shares in Becton Dickinson and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 1,470 shares of Becton Dickinson and Co which is valued at $239,316.Becton Dickinson and Co makes up approximately 0.04% of Fukoku Mutual Life Insurance Co’s portfolio.
Other Hedge Funds, Including , Fil Ltd reduced its stake in BDX by selling 7,389 shares or 7.4% in the most recent quarter. The Hedge Fund company now holds 92,511 shares of BDX which is valued at $15,060,791. Becton Dickinson and Co makes up approx 0.05% of Fil Ltd’s portfolio.Schroder Investment Management Group boosted its stake in BDX in the latest quarter, The investment management firm added 148,739 additional shares and now holds a total of 193,187 shares of Becton Dickinson and Co which is valued at $33,771,019. Becton Dickinson and Co makes up approx 0.06% of Schroder Investment Management Group’s portfolio.Montag A Associates Inc boosted its stake in BDX in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 5,927 shares of Becton Dickinson and Co which is valued at $1,054,354. Becton Dickinson and Co makes up approx 0.14% of Montag A Associates Inc’s portfolio.Douglas Lane Associates reduced its stake in BDX by selling 350 shares or 11.55% in the most recent quarter. The Hedge Fund company now holds 2,681 shares of BDX which is valued at $450,167. Becton Dickinson and Co makes up approx 0.01% of Douglas Lane Associates’s portfolio.
Becton Dickinson and Co closed down -1.56 points or -0.90% at $171.86 with 11,82,371 shares getting traded on Monday. Post opening the session at $173.5, the shares hit an intraday low of $171.21 and an intraday high of $174.09 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Becton Dickinson and Co reported $2.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Nov 3, 2016. Analyst had a consensus of $2.07. The company had revenue of $3231.00 million for the quarter, compared to analysts expectations of $3218.89 million. The company’s revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.94 EPS.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Becton Dickinson and Co was Downgraded by Citigroup to ” Sell” on Sep 23, 2016.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.